- Under the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act -

TOKYO, March 1, 2022  - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. “the Company”) announced the status of acquisition of its own shares as stated below. The acquisition was implemented pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act.

Particulars

  1. Class of shares acquired:    Common stock of the Company
     
  2. Total number of shares acquired:    14,838,800 shares
     
  3. Total amount of acquisition cost:    29,357,828,600 yen
     
  4. Period of acquisition:    From February 3, 2022 to February 28, 2022
     
  5. Method of acquisition:    Purchased on the Tokyo Stock Exchange


(Reference)

  1. Details of the resolution at the meeting of the Board of Directors (announced on February 2, 2022)
     - Class of shares to be acquired:    Common stock of the Company
     - Total number of shares to be acquired:    Up to 29 million shares
                   (Ratio to the total number of shares outstanding
                   [excluding treasury stock]: 1.57%)
     
  2. Accumulated Company’s own shares acquired through February 28, 2022, pursuant to the above board resolution
     - Total number of shares acquired:    14,838,800 shares
     - Total amount of acquisition cost:    29,357,828,600 yen

 

Click below for a copy of the full press release

Contact the Media Relations team
Corporate Advocacy & Relations
Main phone line for Media: +81-3244-3201 
Business hours (JST)
From Monday to Thursday: 8:45 am to 5:45 pm, Friday: 8:45 am to 4:00 pm
(closed on Saturdays, Sundays, national holidays and company holidays)